<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05035589</url>
  </required_header>
  <id_info>
    <org_study_id>MDHITU-TCZ</org_study_id>
    <nct_id>NCT05035589</nct_id>
  </id_info>
  <brief_title>The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 Pneumonia</brief_title>
  <official_title>The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sciberras, Stephen M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mater Dei Hospital, Malta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sciberras, Stephen M.D.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to establish whether tocilizumab has any significant effect on procalcitonin&#xD;
      levels on patients diagnosed with COVID-19 pneumonia requiring intensive care admission. The&#xD;
      effects on other biochemical and clinical markers are also considered.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A retrospective study, involving the first fifty patients treated with tocilizumab for acute&#xD;
      deterioration in COVID-19 pneumonia in the Intensive Care Unit (ICU) at Mater Dei Hospital in&#xD;
      Malta.&#xD;
&#xD;
      The following parameters will be collected from medical records:&#xD;
&#xD;
        -  procalcitonin levels, daily for twenty days or until discharge or death.&#xD;
&#xD;
        -  namely white cell count (WCC), neutrophils, lymphocytes,&#xD;
&#xD;
        -  C-reactive protein (CRP)&#xD;
&#xD;
        -  PaO2/FiO2 ratio (P/F ratio).&#xD;
&#xD;
      This group will be compared to a control group was chosen from patients admitted to the ICU&#xD;
      who were not eligible for tocilizumab treatment, matched to the study group for age, gender,&#xD;
      mode of ventilation required and length of stay in ICU.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 20, 2021</start_date>
  <completion_date type="Anticipated">November 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 20, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Procalcitonin</measure>
    <time_frame>throughout study completion, daily for maximum of 20 days</time_frame>
    <description>effect of Tocilizumab on Procalcitonin levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CRP</measure>
    <time_frame>throughout study completion, daily for maximum of 20 days</time_frame>
    <description>effect of Tocilizumab on CRP levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WCC</measure>
    <time_frame>throughout study completion, daily for maximum of 20 days</time_frame>
    <description>effect of Tocilizumab on WCC levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutrophils</measure>
    <time_frame>throughout study completion, daily for maximum of 20 days</time_frame>
    <description>effect of Tocilizumab on Neutrophils levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocytes</measure>
    <time_frame>throughout study completion, daily for maximum of 20 days</time_frame>
    <description>effect of Tocilizumab on Lymphocytes levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NLR</measure>
    <time_frame>throughout study completion, daily for maximum of 20 days</time_frame>
    <description>effect of Tocilizumab on Neutrophil to Lymphocyte ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>P/F ratio</measure>
    <time_frame>throughout study completion, daily for maximum of 20 days</time_frame>
    <description>effect of Tocilizumab on P/F ratio</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>COVID-19 Pneumonia</condition>
  <condition>ARDS</condition>
  <arm_group>
    <arm_group_label>TCZ</arm_group_label>
    <description>The first 50 patients admitted to the ITU at Mater Dei Hospital with COVID-19 Pneumonia, to whom tocilizumab was administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>50 patients admitted to ITU at Mater Dei Hospital with COVID-19 Pneumonia, who did not receive Tocilizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>Tocilizumab administered at a dose of 8mg/kg up to a maximum of 800mg</description>
    <arm_group_label>TCZ</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        COVID-19 patients treated with tocilizumab single dose therapy in ICU&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed COVID-19 diagnosis&#xD;
&#xD;
          -  Admitted to ITU&#xD;
&#xD;
          -  Tocilizumab treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  none&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mater Dei Hospital</name>
      <address>
        <city>Imsida</city>
        <zip>MSD2090</zip>
        <country>Malta</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Malta</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 26, 2021</study_first_submitted>
  <study_first_submitted_qc>September 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2021</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sciberras, Stephen M.D.</investigator_affiliation>
    <investigator_full_name>Stephen Sciberras</investigator_full_name>
    <investigator_title>Investigator</investigator_title>
  </responsible_party>
  <keyword>COVID-19 Pneumonia</keyword>
  <keyword>Tocilizumab</keyword>
  <keyword>Procalcitonin</keyword>
  <keyword>C-Reactive Protein</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

